FOLFOX Chemotherapy: Efficacy and Tolerability in Advanced Digestive Neuroendocrine Neoplasms (NENs) Abstract #1540

Introduction: FOLFOX has been poorly investigated in digestive NEN (DNENs), mostly in small cohorts.
Aim(s): To analyze efficacy, predictive factors of response and tolerability of FOLFOX in a consecutive series of advanced DNENs.
Materials and methods: Retrospective analysis of patients (pts) receiving FOLFOX IV in 2005-2015, with at least 3-mos follow-up. Objective response (OR) and progression-free survival (PFS) were assessed; prognostic factors analyzed by Cox-regression model.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Medical treatment - Chemotherapy
Presenting Author: Arianna Dal Buono

To read results and conclusion, please login ...

Further abstracts you may be interested in

#2152 Sequential Therapies in Well-Differentiated Gastrointestinal Neuroendocrine Tumors G3 (NET G3): Platinum-Based vs. Platinum-Free Regimens
Introduction: Well-differentiated NET G3 show a longer clinical course than NEC G3, preliminary data indicate they respond poorly to platinum-based therapies.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: MD Arianna Dal Buono
#501 FOLFOX Regimen for Clinically Aggressive Neuroendocrine Tumors: About one Case
Introduction: The treatment for progressive metastatic well-differentiated pancreatic neuroendocrine tumors is based on adriamycin and streptozotocin chemotherapy, which achieves more than 60% tumor regression. However, severe adverse effects are common.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Doctor Leïla Bengrine-Lefevre
#1387 FOLFOX in Neuroendocrine Tumors
Introduction: Favorable toxicity profile and significant antitumor activity of FU-oxaliplatin in several malignancies led us to evaluate FOLFOX in advanced neuroendocrine carcinomas (NETs).
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Medical treatment - Chemotherapy
Presenting Author: Marjorie Faure
Authors: Faure M, Raoul J L, Autret A, Mineur L, ...
#2197 Tumor Necrosis of Primary Malignancy Affects Survival and Outcome in Patients with Liver Metastases from Neuroendocrine Tumors
Introduction: Reliable biomarkers represent a crucial unmet need in the management of neuroendocrine tumors. Tumor necrosis has been suggested to have a prognostic value in selected solid tumors but is not included in established WHO NET Grading Systems. However, little is known regarding the influence of tumor necrosis on tumor progression and prognosis in patients with liver metastasis from neuroendocrine tumors.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Biomarkers
Presenting Author: Dr. med. Georgi Atanasov
#568 Efficacy of Everolimus and Tolerability with Long-Term Use
Introduction: Predictors of response to Everolimus in neuroendocrine tumors and long-term safety data are lacking.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Maximilian Heetfeld